INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://talenta.usu.ac.id/IJNPC <p style="text-align: justify;">International Journal of Nasopharyngeal Carcinoma (IJNPC) is a peer review journal that publishes research findings from disciplines related to nasopharyngeal carcinoma. This journal was published by the Center of Excellence Nasopharyngeal Carcinoma Universitas Sumatera Utara, collaborated with TALENTA Publisher Universitas Sumatera Utara. The publication of papers is quarter yearly, published in March, June, September, and December. The journal is purposed to provide international sources of information to doctors and other health professionals who are interested in nasopharyngeal carcinoma. This journal is expected to improve communication between researchers so that it has an impact on the development of knowledge regarding nasopharyngeal carcinoma and stimulates further research related to head and neck surgical oncology, diagnosis, and clinical management.</p> <p style="text-align: justify;">Articles in the International Journal of Nasopharyngeal Carcinoma will be reviewed by experts in the leading nasopharyngeal carcinoma. This journal publishes original research, review articles and case reports. We accept submissions from all over the world. All submitted articles are not in the condition of being submitted to other journals and have never been published elsewhere.</p> TALENTA PUBLISHER en-US INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA 2656-9027 <div id="coptf"> <p align="justify">The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to The International Journal of Nasopharyngeal Carcinoma (IJNPC)<span id="result_box" class="" lang="en"><span class="">&nbsp;as well as TALENTA Publisher Universitas Sumatera Utara</span></span> as publisher of the journal.</p> <p align="justify">Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from The International Journal of Nasopharyngeal Carcinoma (IJNPC).</p> <p align="justify">The Copyright Transfer Form can be downloaded <a href="https://drive.google.com/file/d/1YEYJCUGxuqfoUuCw6sy2VZE3grr0ygFI/view?usp=sharing" target="_blank" rel="noopener">here.&nbsp;</a><br>The copyright form should be signed originally and sent to<a href="https://talenta.usu.ac.id/IJNPC/jcontact"> the Editorial Office</a> in the form of original mail or scanned document.</p> </div> Chemotherapy Management of Nasopharyngeal Carcinoma Patient in General Hospital Haji Adam Malik Medan : A Case Report https://talenta.usu.ac.id/IJNPC/article/view/6344 <p><strong>Introduction</strong><strong>: </strong></p> <p>Nasopharyngeal carcinoma (NPC) is in the fourth place according to the most most common malignancies in Indonesians. Three types of nasopharyngeal carcinoma are squamous cell, non-keratinizing, and undifferentiated carcinoma.</p> <p><strong>Case report: </strong></p> <p>A 51-year-old man came to the ENT-Head and Neck Surgery Outpatient clinic of General Hospital Haji Adam Malik Medan on November 2, 2020 with main complaint of lump on the neck and nasal congestion. The patient underwent a contrast-enhanced nasopharyngeal MSCT scan with the result: T2N0M0. The histopathology results: Non-Keratinizing Squamous Cell Carcinoma. The patient was given 70 gy of Chemoradiation (CRT) followed by adjuvant chemotherapy with Cisplatin + 5 Fu. </p> <p><strong>Conclusion: </strong></p> <p>There was no visible mass on the nasopharynx after using this combination therapy</p> Saurma Otri Sonya Simanjuntak Farhat Farhat Elvita Rahmi Daulay Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 36 37 10.32734/ijnpc.v3i02.6344 Effects of Cisplatin on Superoxide Anion, Sod, Apoptosis and Cytoplasmic p21Expression in C666-1 Cell Lines Undifferentiated Nasopharyngeal Cancer https://talenta.usu.ac.id/IJNPC/article/view/6343 <p><strong>Introduction</strong><strong>:</strong></p> <p>ROS, a mechanism in CIS pathogenesis, causes toxicity when cisplatin is administered. Superoxide anion (O2-), a radical anion, part of ROS that is initially triggered after a part of oxygen enters a living cell. The main principle of this enzyme is to work as a protection against oxygen toxicity and plays a role as body catalyst. The p21 has a main function in the regulation of cell cycle progression. It is able to regulate cell proliferation through its association with PCNA and DNA polymerase accessory factor as a part of cell regulation and apoptosis.</p> <p><strong>Objective: </strong></p> <p>To study the effects of cisplatin on the increase or decrease of O2-, SOD, proliferation (MTT), apoptosis and cytoplasmic p21 expression in C666-1 cell lines.</p> <p><strong>Methods</strong><strong>: </strong></p> <p>An experimental study with a post control group design and cisplatin in group dosages of 7.86 µg/mL, 15.36 µg/mL and 30.72 µg/mL.</p> <p><strong>Result</strong><strong>s: </strong></p> <p>The mean difference of O2- in C666-1 cell lines between cisplatin groups was not significant (P value 0.871, P&gt;0.05). The mean difference of SOD in C666-1 cell lines was highly significant (P value 0.001, P&lt;0.05) showing a significant increase of SOD. The mean difference of C666-1 cell lines proliferation (MTT) between cisplatin groups was not significant (P value 0.094, P&gt;0.05). The mean difference of C666-1 cell lines apoptosis between cisplatin groups was not significant (P value 0.104, P&gt;0.05). Cytoplasmic p21 highest expression was found at the 30.72 dosage obtained from 24 hours observation.</p> <p><strong>Conclusion: </strong></p> <p>Increase of SOD after a high dose of cisplatin administration, due to the balance between ROS production and detoxification process caused by antioxidants (SOD), will affect cancer cells to proliferate and survive. Increase of apoptosis at the highest dose found in this study, showed that apoptosis was induced by cisplatin. Therefore, antioxidant administration may be considered for nasopharyngeal cancer patients.</p> Imam Prabowo Edi Widjajanto Aris Widodo Karisma Prameswari Patria Mahatmi Handoko Nugroho Yossarsongko Pudji Rahaju Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 38 41 10.32734/ijnpc.v3i02.6343 Audiometry Finding in Nasopharyngeal Carcinoma Patients in ENT-HN Department of Mohammad Hoesin General Hospital Palembang 1 June 2016-1 June 2020 https://talenta.usu.ac.id/IJNPC/article/view/6321 <p><strong>Introduction</strong><strong>: </strong></p> <p>Nasopharyngeal Carcinoma (NPC) is a type of epithelial carcinoma that arises from the nasopharynx mucosal lining that usually develops in the fossa of Rosenmüller. One of NPC’s initial signs is hearing loss.</p> <p><strong>Objective: </strong></p> <p>This study aims to determine the audiometry of patients with nasopharyngeal carcinoma in the ENT-HN department of Mohammad Hoesin General Hospital Palembang 1 June 2016-1 June 2020.</p> <p><strong>Methods</strong><strong>: </strong></p> <p>This research is a descriptive observational study with cross-sectional study design using medical records of patients with nasopharyngeal carcinoma at Mohammad Hoesin General Hospital Palembang 1 June 2016 – 1 June 2020 who met the inclusion criteria.</p> <p><strong>Result</strong><strong>s: </strong></p> <p>From 48 samples, 42 samples (87,5%) were male, and 14 samples (29,2%) were included in the age range of 47-52 years. There were 18 samples (37,5%) suffering from a moderate degree of deafness. NPC patients mostly had conductive hearing loss (72,9%). Most of the sample suffered from bilateral hearing loss (75%). The majority of NPC patients had already been in stage IV (70,8%). It was found that NPC patients with stage IV suffered the most from conductive hearing loss (79,4%).</p> <p><strong>Conclusion: </strong></p> <p>NPC patients from 1 June 2016 – 1 June 2020 at ENT-HN Department of Mohammad Hoesin General Hospital Palembang were mostly male with an age range of 47-52 years who suffered from bilateral moderate conductive hearing loss and had already been in stage IV. It was found that most patients with stage IV of NPC had conductive hearing loss</p> Denny Satria Utama Sella Vanessa Lie Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 42 44 10.32734/ijnpc.v3i02.6321 Covid-19 Vaccination in Nasopharyngeal Carcinoma Patients during COVID-19 Pandemic https://talenta.usu.ac.id/IJNPC/article/view/6323 <p><strong>Introduction:</strong></p> <p>Nasopharyngeal carcinoma (NPC) is one kind of cancer that is the most common type of head and neck malignancy, arising from the posterior and lateral parts of the nasopharynx especially from torus tubarius or pharyngeal recess or the other name is Rosenmüller fossa. This shows significant differences from other head and neck cancers, clinical behavior, cause, epidemiology, treatment, as well as prognosis. Clinical trials of COVID-19 vaccines with better follow-up will provide useful data on vaccine advantages in patients receiving cancer treatment, due to the absence of complete data to determine the relationship between active oncology treatment and the power to induce immunity to COVID-19 using the vaccine.</p> <p><strong>Discussion: </strong></p> <p>The primary aim of vaccines is to produce stimulation by the antigen we desire in the presence of sufficient infection to elicit memory immunity with tolerable protection.[15] Due to the increasing frailty of cancer patients with infection as well as deaths from COVID-19, there is an urgent need to vaccinate patients with COVID-19 cancer. Various considerations for the protection and benefits that are expected to have an effect with treatment due to their standart management and changes in the immune system of patients with malignancies.</p> <p><strong>Conclusion</strong></p> <p>The COVID-19 vaccine, granted approved or permitted, will be considered the basic of prevention of this COVID-19 pandemic for patients with nasopharyngeal carcinoma. There are advantages and disadvantages about Covid-19 vaccine. Then, a quality direction on clinical trials of patients with cancer and COVID-19 vaccines becomes very attractive. Finally, comprehensive oncological care requires cancer patients to be prioritized for the COVID-19 vaccine</p> Irnanda Warda Rizki Nasution Farhat Farhat Elvita Rahmi Daulay Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 45 47 10.32734/ijnpc.v3i02.6323 Management of Nasopharyngeal Carcinoma Patient in General Hospital Haji Adam Malik Medan https://talenta.usu.ac.id/IJNPC/article/view/6322 <p><strong>Introduction</strong><strong>: </strong></p> <p>Nasopharyngeal carcinoma (NPC) is a malignancy of squamous cells on nasopharyngeal epithelial layer with Rosenmuller fossa with a high incidence especially in Asian region. There is three different histologic subtypes, namely squamous cell carcinoma, nonkeratinizing carcinoma, and undifferentiated carcinoma. Principle of management NPC is radiotherapy because of this kind of carcinoma highly radiosensitive and is the mainstay of treatment for all stages. But in advance case, we need combinatio of radiotherapy and chemotherapy</p> <p><strong>Case report</strong><strong>: </strong></p> <p>We report a patient which came to the ENT-Head and Neck Surgery Outpatient Clinic of General Hospital Haji Adam Malik Medan with complaint of tinnitus in the right ear and nasal congestion on the right side. The patient then performed a contrast-enhanced nasopharyngeal MSCT scan with the result: T2aN0M0. The histopathology results : Non Keratinizing Squamous Cell Carcinoma. The patient was given 70 gy of Concurent Chemoradiation (CRT) followed by adjuvant chemotherapy with Cisplatin and 5 Flourouracil (FU).</p> <p><strong>Conclusion: </strong></p> <p>There was no visible mass on the nasopharynx after using this combination Radiation and Chemotherapy</p> Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 48 50 10.32734/ijnpc.v3i02.6322 New Role Management Nasopharyngeal Carcinoma Patient in General Hospital Haji Adam Malik Medan during COVID-19 Pandemic https://talenta.usu.ac.id/IJNPC/article/view/6320 <p><strong>Introduction: </strong></p> <p>Nasopharyngeal carcinoma (NPC) is a type of squamous cell carcinoma that develops from the nasopharyngeal epithelial cells and has become one among the most popular frequent malignancy in the head and neck. When patients with cancer are diagnosed with COVID-19, more intense surveillance or treatment should be considered.</p> <p><strong>Discussion: </strong></p> <p>In the COVID 19 pandemic, Personal protection provisions should be strengthened. created for cancer patients and cancer survivors. To avoid the spread of COVID-19, many improvements have been made in the treatment of NPC patients at the Haji Adam Malik General Hospital in Medan.</p> <p><strong>Conclusion: </strong></p> <p>The management carried out on NPC patients, there are several examinations that the patient needs to do first in the COVID 19 pandemic at the General Hospital Haji Adam Malik Medan</p> Sholahuddin Adlan Simatupang Farhat Farhat Elvita Rahmi Daulay Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 51 53 10.32734/ijnpc.v3i02.6320 Radiotherapy Management of Nasopharyngeal Carcinoma Patient in General Hospital Haji Adam Malik Medan: A Case Report https://talenta.usu.ac.id/IJNPC/article/view/6324 <p><strong>Introduction</strong><strong>: </strong></p> <p>Nasopharyngeal carcinoma (NPC) is a head and neck malignancy with a high incidence especially in Asian region. NPC has highly prevalence in head and neck cancer with most of the type is squamous cell type with three different histologic subtypes, namely squamous cell carcinoma, nonkeratinizing carcinoma, and undifferentiated carcinoma. Principle of management NPC is radiotherapy because of this kind of carcinoma highly radiosensitive and is the mainstay of treatment for all stages.</p> <p><strong>Case report: </strong></p> <p>A 33-year-old woman came to the ENT-Head and Neck Surgery Outpatient clinic of General Hospital Haji Adam Malik Medan on March, 2021. The patient was diagnosed with Nasopharynx carcinoma, with complaints of nose bleeds and, nasal congestion. History of consuming salted fish was found. History of cooking food with flavoring was found. The patient then performed a non-contrast-enhanced nasopharyngeal MSCT scan on February 17th, 2021 with the result: Left nasopharyngeal mass that extends to the left torus tobarius, left rossenmuller fossa crossing to the right nasopharyngeal midline (T1N0M0). The histopathological results were carried out at the Vina Estetika Hospital: Keratinizing Squamous Cell Carcinoma. The patient then performed a contrast-enhanced nasopharyngeal MSCT scan on March 3rd 2021 with the result: a left-sided nasopharyngeal mass with a rosenmuller fossa and an obliterated Tobarius torus was seen. Nasopharyngeal mass (T1N0M0). The patient was given 70 gy of Radiotherapy on March 18th 2021. After radiation 35 times on May 18th 2021, the patient was evaluated on the next 8 weeks.</p> <p><strong>Conclusion: </strong></p> <p>Using radiotherapy alone in this patient is the best therapy for this patient. Beside that, early diagnosis in NPC was giving better result of this management</p> Copyright (c) 2021 INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA https://creativecommons.org/licenses/by-nc-sa/4.0 2021-06-20 2021-06-20 3 02 54 56 10.32734/ijnpc.v3i02.6324